Aptorum Group Ltd
NASDAQ:APM

Watchlist Manager
Aptorum Group Ltd Logo
Aptorum Group Ltd
NASDAQ:APM
Watchlist
Price: 0.71 USD -5.35% Market Closed
Market Cap: 5.1m USD

Gross Margin
Aptorum Group Ltd

0%
Current
4%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
0%
=
Gross Profit
5.3k
/
Revenue
0

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
UK
Aptorum Group Ltd
NASDAQ:APM
5.1m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
329.3B USD
70%
US
Amgen Inc
NASDAQ:AMGN
155.5B USD
62%
US
Gilead Sciences Inc
NASDAQ:GILD
131.5B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.9B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
118.9B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
62.8B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
29.8B EUR
90%

Aptorum Group Ltd
Glance View

Market Cap
5.1m USD
Industry
Biotechnology

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.

APM Intrinsic Value
Not Available
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
0%
=
Gross Profit
5.3k
/
Revenue
0
What is the Gross Margin of Aptorum Group Ltd?

Based on Aptorum Group Ltd's most recent financial statements, the company has Gross Margin of 0%.

Back to Top